Search results for "Extensively Drug-Resistant Tuberculosis"

showing 4 items of 4 documents

Are moxifloxacin and levofloxacin equally effective to treat XDR tuberculosis?

2017

International audience; Background: Moxifloxacin retains partial activity against some fluoroquinolone-resistant mutants of Mycobacterium tuberculosis. Levofloxacin is presumed to be as active as moxifloxacin against drug-susceptible tuberculosis and to have a better safety profile.Objectives: To compare the in vivo activity of levofloxacin and moxifloxacin against M. tuberculosis strains with various levels of fluoroquinolone resistance.Methods: BALB/c mice were intravenously infected with 106M. tuberculosis H37Rv and three isogenic mutants: GyrA A90V, GyrB E540A and GyrB A543V. Treatment with 50 or 100 mg/kg levofloxacin and 60 or 66 mg/kg moxifloxacin was given orally every 6 h, for 4 we…

0301 basic medicineMicrobiology (medical)Tuberculosis[SDV.SP.MED] Life Sciences [q-bio]/Pharmaceutical sciences/MedicationmiceExtensively Drug-Resistant Tuberculosis030106 microbiologyMicrobial Sensitivity TestsMicrobiologyMycobacterium tuberculosis03 medical and health sciences0302 clinical medicine[SDV.SP.MED]Life Sciences [q-bio]/Pharmaceutical sciences/MedicationLevofloxacinMoxifloxacinIn vivo[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseasesmedicineAnimalsPharmacology (medical)heterocyclic compounds030212 general & internal medicinePharmacologyMice Inbred BALB ClevofloxacinbiologyChemistry[ SDV.SP.MED ] Life Sciences [q-bio]/Pharmaceutical sciences/MedicationExtensively drug-resistant tuberculosisMycobacterium tuberculosisbiochemical phenomena metabolism and nutritionmedicine.diseasebiology.organism_classificationbacterial infections and mycosesFluoroquinolone resistanceAnti-Bacterial Agents3. Good health[ SDV.MHEP.MI ] Life Sciences [q-bio]/Human health and pathology/Infectious diseasesDisease Models AnimalSafety profileTreatment OutcomeInfectious Diseasestuberculosis[SDV.MHEP.MI] Life Sciences [q-bio]/Human health and pathology/Infectious diseasesbacteriamoxifloxacinFluoroquinolonesmedicine.drug
researchProduct

Trend in rifampicin-, multidrug- and extensively drug-resistant tuberculosis in Italy, 2009-2016

2018

In Italy, rifampicin-resistant and MDR-TB were high in foreign-born persons, but decreased from 2009 to 2016

0301 basic medicinePulmonary and Respiratory MedicineExtensively Drug-Resistant TuberculosisAntitubercular AgentsEmigrants and ImmigrantsAntitubercular Agents; Emigrants and Immigrants; Extensively Drug-Resistant Tuberculosis; Humans; Italy; Mycobacterium tuberculosis; Rifampin; Tuberculosis Multidrug-ResistantMycobacterium tuberculosis03 medical and health sciences0302 clinical medicineTuberculosis Multidrug-Resistantpolycyclic compoundsmedicineTuberculosisHumansbiologybusiness.industryExtensively drug-resistant tuberculosisMycobacterium tuberculosisMultidrug-Resistantmedicine.diseasebiology.organism_classificationVirology030104 developmental biology030228 respiratory systemItalyRifampinbusinessRifampicinmedicine.drug
researchProduct

Reference set of Mycobacterium tuberculosis clinical strains: A tool for research and product development

2018

TheMycobacterium tuberculosiscomplex (MTBC) causes tuberculosis (TB) in humans and various other mammals. The human-adapted members of the MTBC comprise seven phylogenetic lineages that differ in their geographical distribution. There is growing evidence that this phylogenetic diversity modulates the outcome of TB infection and disease. For decades, TB research and development has focused on the two canonical MTBC reference strains H37Rv and Erdman, both of which belong to Lineage 4. Relying on only a few laboratory-adapted strains can be misleading as study results might not be directly transferrable to clinical settings where patients are infected with a diverse array of strains, includin…

Bacterial DiseasesResearch FacilitiesExtensively Drug-Resistant TuberculosisLineage (evolution)DiseaseAnimal PhylogeneticsMedicine and Health SciencesPhylogenyData Management0303 health sciencesGeographyPhylogenetic treeStrain (biology)QRGenomics3. Good healthActinobacteriaPhylogeneticsPhylogeographyInfectious DiseasesBiogeographyMycobacterium tuberculosis complexMedicineResearch LaboratoriesResearch ArticleComputer and Information SciencesTuberculosisTuberculosiScienceBiologyResearch and Analysis MethodsMycobacterium tuberculosis03 medical and health sciencesGenomic MedicineGeneticsmedicineTuberculosisHumansEvolutionary SystematicsTaxonomy030304 developmental biologyEvolutionary BiologyPopulation BiologyBacteria030306 microbiologyEcology and Environmental SciencesOrganismsBiology and Life SciencesGenetic VariationMycobacterium tuberculosisTropical Diseasesbiology.organism_classificationmedicine.diseaseGenòmicaPhylogenetic diversityEvolutionary biologyEarth SciencesZoologyPopulation Genetics
researchProduct

2015

Globally, there is substantial concern regarding the challenges of treating complex drug resistance patterns in multidrug resistant tuberculosis cases. Utilising data from three different settings (Estonia, Latvia, Romania) we sought to contrast drug susceptibility profiles for multidrug resistant tuberculosis cases, highlight the difficulties in designing universal regimen, and inform future regimen selection. Demographic and microbiological surveillance data for multidrug resistant tuberculosis cases from 2004-13 were analysed. High levels of additional resistance to currently recommended second line drugs were seen in all settings, with extensive variability between countries. Accurate d…

medicine.medical_specialtyMultidisciplinaryTuberculosisCross-sectional studybusiness.industryMulti-drug-resistant tuberculosisExtensively drug-resistant tuberculosisDrug resistancemedicine.diseaseMultiple drug resistanceRegimenPharmacotherapymedicineIntensive care medicinebusinessPLOS ONE
researchProduct